Oscar Health GLP-1 Coverage & Prior Authorization Guide: The PG070 Pathway Most Plans Don't Include (2026)

Oscar Health is one of the few ACA Marketplace insurers that keeps a real clinical pathway to cover GLP-1s for weight loss — its Weight Loss Agents clinical guideline (PG070) names Wegovy, Saxenda, and Zepbound as agents that can be approved with prior authorization. The catch is structural: that pathway only applies to members whose specific plan benefit includes anti-obesity drugs, and most Oscar Marketplace plans exclude weight-loss medications outright. So the honest picture is a genuine coverage door that most members will find locked by their own benefit design. GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro) run under a separate policy and are far more widely covered, also with PA.

Bottom line: Oscar can cover it, but your plan probably won't

• Oscar's Weight Loss Agents clinical guideline (PG070) explicitly lists Wegovy, Saxenda, and Zepbound as weight-loss agents that CAN be approved via prior authorization — Oscar has a pathway to cover obesity GLP-1s, unlike insurers that categorically exclude them.
• Coverage is entirely benefit-dependent: PG070 “only applies to members whose Plan covers prescription drugs prescribed for the treatment of obesity,” and such coverage “varies depending on a member’s benefit policy” — being in the guideline does not mean a given plan’s benefit includes it.
• All weight-loss GLP-1s require prior authorization; none are open-access. Diabetes-indicated GLP-1s live under a separate guideline (PG152) and also carry PA.
• Adult initial PA criteria (PG070): BMI ≥ 30, OR BMI ≥ 27 with at least one weight-related comorbidity (cardiovascular disease, dyslipidemia, hypertension, metabolic syndrome, OSA, type 2 diabetes, MASLD); documentation within the past month; used as an adjunct to a reduced-calorie diet and increased physical activity; not combined with other weight-loss agents.
• Reauthorization requires documented continued lifestyle modification AND at least 5% baseline weight loss; GLP-1 agents are reauthorized for up to 6 months.
• Industry context (KFF): among federally-facilitated ACA Marketplace plans, only about 1% cover Wegovy for obesity and essentially none cover Zepbound for obesity, while Ozempic (diabetes) is on about 82% of formularies — anti-obesity drugs are not required Essential Health Benefits, so ACA plans may exclude them.
• 2025-2026 update: the current PG070 removed the earlier requirement of 6 months’ prior participation in a comprehensive weight-management program, added oral Wegovy, and expanded the comorbidity list.
• Appeals follow the ACA framework: internal appeal to Oscar, then external independent review; some specialty PA reviews are delegated to EviCore, in which case the first-level appeal routes through EviCore.

Prior-authorization criteria (PG070)

• Recent documentation (within the past month) of adult BMI ≥ 30, OR BMI ≥ 27 with ≥ 1 weight-related comorbidity (CVD, dyslipidemia, hypertension, metabolic syndrome, OSA, type 2 diabetes, MASLD).
• Baseline (pre-treatment) body weight collected in a provider’s office.
• Medication used as an adjunct to a reduced-calorie diet and increased physical activity.
• Not combined with other weight-loss products or same-class agents unless the label allows.
• Initial approval up to 6 months for Wegovy, Saxenda, and Zepbound.
• Reauthorization (up to 6 months): documented continued lifestyle modification plus ≥ 5% weight loss from baseline.

What Oscar's policy says

“Coverage of prescription drugs prescribed for the treatment of obesity or for use in any weight reduction, weight loss, or dietary control varies depending on a member’s benefit policy.”

Source: Oscar Clinical Guideline: Weight Loss Agents (PG070). This is the sentence that determines whether the rest of the guideline ever applies to you — coverage is a function of your specific benefit, not of the guideline’s existence.

“This Clinical Guideline only applies to members whose Plan covers prescription drugs prescribed for the treatment of obesity or for use in any weight reduction, weight loss, or dietary control.”

Source: Oscar Clinical Guideline: Weight Loss Agents (PG070). If your plan document carries a weight-loss-drug exclusion, no amount of clinical documentation can force approval under PG070 — the first step is always to confirm the benefit itself.

“The member has achieved or sustained clinically meaningful weight loss (collected in a provider’s office), defined as: For adults, at least 5% of baseline body weight.”

Source: Oscar Clinical Guideline: Weight Loss Agents (PG070). This is the reauthorization gate — at renewal, your prescriber must document at least 5% baseline weight loss (measured in-office) plus continued lifestyle modification to keep coverage going.

How to appeal an Oscar denial

• File an internal appeal to Oscar first. Some specialty PA reviews are delegated to EviCore — in that case, the first-level appeal runs through EviCore rather than Oscar directly.
• Typical Oscar timeframes: pre-service appeals around 30 days, post-service around 60 days, and urgent/expedited around 72 hours.
• If the internal appeal is upheld (denied), request an external independent review (IRO) — generally within about 4 months of the final internal denial.
• Exact deadlines vary by state and plan document — check your Evidence of Coverage and the specific denial letter for the clauses and dates that apply to you.

The PG070 criteria quoted here were extracted from published versions of the guideline (references dated through December 2025); Oscar’s live index may list a newer version, but the core structure — obesity coverage is benefit-dependent, PA is required, BMI ≥ 30 or ≥ 27 with a comorbidity, and 5% weight loss for reauthorization — has been stable across versions. The KFF Marketplace figures are KFF’s market-wide analysis, not Oscar-specific. Confirm exact criteria and deadlines in your own plan documents before filing.

Further reading

• Cheapest GLP-1 without insurance: buyer's guide
• Best semaglutide providers